Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
CymaBay Therapeutics, Inc is a biotechnology business based in the US. CymaBay Therapeutics shares (CBAY) are listed on the NASDAQ and all prices are listed in US Dollars. CymaBay Therapeutics employs 22 staff and has a market cap (total outstanding shares value) of USD$582.8 million.
|Latest market close||USD$7.2|
|52-week range||USD$1.21 - USD$8.71|
|50-day moving average||USD$6.8773|
|200-day moving average||USD$4.5041|
|Wall St. target price||USD$12.73|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.375|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-0.83%|
|1 month (2020-11-05)||-15.29%|
|3 months (2020-09-04)||24.03%|
|6 months (2020-06-05)||88.48%|
|1 year (2019-12-05)||333.73%|
|2 years (2018-12-04)||-17.71%|
|3 years (2017-12-05)||-15.99%|
|5 years (2015-12-04)||400.00%|
|Gross profit TTM||USD$-64,579,000|
|Return on assets TTM||-22.78%|
|Return on equity TTM||-39.59%|
|Market capitalisation||USD$582.8 million|
TTM: trailing 12 months
There are currently 6.3 million CymaBay Therapeutics shares held short by investors – that's known as CymaBay Therapeutics's "short interest". This figure is 5.5% up from 6.0 million last month.
There are a few different ways that this level of interest in shorting CymaBay Therapeutics shares can be evaluated.
CymaBay Therapeutics's "short interest ratio" (SIR) is the quantity of CymaBay Therapeutics shares currently shorted divided by the average quantity of CymaBay Therapeutics shares traded daily (recently around 1.7 million). CymaBay Therapeutics's SIR currently stands at 3.76. In other words for every 100,000 CymaBay Therapeutics shares traded daily on the market, roughly 3760 shares are currently held short.
However CymaBay Therapeutics's short interest can also be evaluated against the total number of CymaBay Therapeutics shares, or, against the total number of tradable CymaBay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CymaBay Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 CymaBay Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.0925% of the tradable shares (for every 100,000 tradable CymaBay Therapeutics shares, roughly 93 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CymaBay Therapeutics.
Find out more about how you can short CymaBay Therapeutics stock.
We're not expecting CymaBay Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CymaBay Therapeutics's shares have ranged in value from as little as $1.21 up to $8.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CymaBay Therapeutics's is 1.5444. This would suggest that CymaBay Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.